Holen Sie sich die Stockscreener-App
1.77
4.84%
-0.09
Handel nachbörslich:
1.70
-0.07
-3.95%
Schlusskurs vom Vortag:
$1.86
Offen:
$1.85
24-Stunden-Volumen:
1.35M
Relative Volume:
5.07
Marktkapitalisierung:
$74.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.75M
KGV:
-0.5331
EPS:
-3.32
Netto-Cashflow:
$-30.91M
1W Leistung:
-16.51%
1M Leistung:
-15.31%
6M Leistung:
-46.36%
1J Leistung:
-14.90%
1-Tages-Spanne:
$1.66
$1.9499
1-Wochen-Bereich:
$1.66
$2.18
52-Wochen-Spanne:
$1.66
$4.45
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
Cellectar Biosciences Inc
Sektor
Branche
Telefon
(608) 441-8120
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Vergleichen Sie CLRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CLRB | 1.77 | 74.63M | 0 | -37.75M | -30.91M | -3.32 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-07-01 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-21 | Fortgesetzt | ROTH Capital | Buy |
| 2019-09-13 | Eingeleitet | ROTH Capital | Buy |
| 2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
Cellectar Biosciences Inc reports results for the quarter ended September 30Earnings Summary - XM
Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cellectar corrects accounting firm consent in SEC filing By Investing.com - Investing.com Australia
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest Update - MarketBeat
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update - The Bakersfield Californian
Cellectar Reports Positive Phase 2 Results, Secures $19.4M in Warrant Exercises | CLRB Stock News - StockTitan
SEC Form 10-Q filed by Cellectar Biosciences Inc. - Quantisnow
Cellectar Biosciences (CLRB) Scheduled to Post Earnings on Monday - Defense World
Cellectar Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
ADAR1 Capital Management, LLC Expands Stake in Cellectar Bioscie - GuruFocus.com
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 - GlobeNewswire
Cellectar Partners With NorthStar For Ac-225 Supply - Contract Pharma
Cellectar secures Ac-225 supply for cancer drug development - Investing.com
Cellectar Secures 10-Year Supply of Rare Cancer Treatment Isotope for Clinical Trials | CLRB Stock News - StockTitan
Cellectar Biosciences and SpectronRx Partner to Manufacture - GlobeNewswire
Cellectar Biosciences (CLRB) Scheduled to Post Quarterly Earnings on Monday - MarketBeat
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer - The Manila Times
CLRB (Cellectar Biosciences) 3-Year EBITDA Growth Rate : 25.40% (As of Jun. 2024) - GuruFocus.com
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 - The Manila Times
Cellectar Biosciences to Report Third Quarter Financial - GlobeNewswire
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 - GlobeNewswire
Cellectar's Breakthrough WM Cancer Drug Data Set for Major ASH 2024 Presentation | CLRB Stock News - StockTitan
Rosalind Advisors Inc. Increases Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - MarketBeat
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q - GlobeNewswire
Sequoia Financial Advisors LLC Purchases New Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Current and Future Analysis of Neuroblastoma Therapeutic - openPR
Waldenstrom Macroglobulinemia Market to Show Remarkable - openPR
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Sees Large Increase in Short Interest - MarketBeat
Bone Cancer Drugs Market Next-Generation Dynamic Growth - openPR
Cellectar Biosciences (NASDAQ:CLRB) Receives Outperform Rating from Oppenheimer - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Given Outperform Rating at Oppenheimer - MarketBeat
Oppenheimer maintains Outperform rating on Cellectar Biosciences By Investing.com - Investing.com Canada
Cellectar Biosciences (NASDAQ:CLRB) Shares Cross Above Fifty Day Moving Average – Here’s Why - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Stock Passes Above 50 Day Moving AverageTime to Sell? - MarketBeat
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - GlobeNewswire
XTX Topco Ltd Purchases 51,413 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Upgraded at StockNews.com - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Upgraded to "Sell" by StockNews.com - MarketBeat
Cellectar Biosciences (NASDAQ:CLRB) Stock Quotes, Forecast and News Summary - Benzinga
Was there any good news for Cellebrite DI Ltd (CLBT) stock in the last session? - US Post News
Trust Investment Advisors Acquires Shares of 24,250 Celestica Inc. (NYSE:CLS) - MarketBeat
Cellucare Reviews (DO NOT BUY YET) Any Side Effects or Customer Complaints in 2024? - Businessday
Cardlytics Inc [NASDAQ: CDLX] Sees Increase in Stock Value - Knox Daily
CLS’s Stock Journey: What Investors Need to Know About Celestica, Inc.’s Performance - The InvestChronicle
Ratios Revealed: Decoding Celestica, Inc. (CLS)’s Financial Health - The Dwinnex
Celestica, Inc. (CLS) presents a great opportunity, but the stock is slightly undervalued - US Post News
Cellecor Gadgets Limted acquires 100% equity of Cellecor Foundation towards its CSR initiatives and commitments - APN News
Cellecor Gadgets shares rally 5% to hit new 52-week high; check key trigger - ET Now
Renaissance Technologies LLC Sells 12,126 Shares of Chemed Co. (NYSE:CHE) - Defense World
Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com - Defense World
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):